NEWS Release

Wex Announces Tectin™ Phase IIa Final Results Presented Today at the 3rd. World Congress World Institute of Pain

Date: September 23, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

Vancouver, British Columbia, September 24, 2004 - International Wex Technologies Inc. (TSX: WXI), a pharmaceutical company that develops drugs for the management of pain, today announced the presentation of two posters relating to its Phase IIa study of tetrodotoxin (Tectin™), an investigational treatment for the management of severe cancer-related pain, at the 3rd World Congress World Institute of Pain in Barcelona, Spain.

Dr. Ed Sellers, Director of Psychopharmacology and Dependence Research Unit, Centre for Research in Women's Health, Sunnybrook and Women's College Health Sciences Centre and President and CEO of Ventana Clinical Research Corporation, was the Senior Medical and Scientific Consultant for this study.   Dr. Sellers used a novel graphic display of the results called the Uniform Mosaic Display (UMD) to summarize the overall individual patient responses over several days.  Dr. Sellers concluded that the UMD may be useful in identifying subjects who benefited from treatment but was not necessarily reflected using the predetermined primary objective pain intensity criteria.  He also added that the UMD may aid in designing further analyses or identifying useful endpoints or composite endpoints for future studies.  He concluded that Tectin™ is effective in reducing pain in subjects with otherwise intractable cancer pain and also appears to improve some components of pain not reflected by traditional pain endpoints.

A second poster which was prepared by Dr. Neil Hagen, head of Division of Palliative Medicine, department of Oncology at the University of Calgary and the lead Investigator of the study will also be presented which shows that Tectin™ administered intramuscularly for four days has the potential to produce sustained relief of pain that extends well beyond the treatment period.  This particularity may reflect a prolonged disruption of the nerve sensitization, maintaining subjects' pain relief.

Based on the findings from the Phase IIa study, Wex recently announced the launch of a pivotal trial implemented at 23 treatment centers across Canada.   This multi-centre trial is a randomized double-blind and placebo-controlled study comparing the efficacy and safety of Tectin™ in patients with moderate to severe inadequately controlled cancer pain.

About International Wex Technologies Inc.

International Wex Technologies Inc. is a pharmaceutical company dedicated to the discovery of new therapeutic agents for the treatment of moderate to severe pain, symptom relief associated with addiction withdrawal from opioid abuse, and medicines designed for local and regional anaesthesia.   The Company's principle business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for North American, European and International markets.  The Company also generates revenues from sales of generic products manufactured at its facility in China .

Forward Looking Statement Disclaimer

Statements in this news release are forward-looking statements which may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "anticipates", "intends", "expects" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, WEX 's stage of development, product revenues which are difficult to predict, foreign currency exchange risk, additional capital requirements, risks associated with the completion of clinical trials, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

For additional information on our products call Don Evans or Gordon Stanley, Corporate Communications at 604-683-8880 or 1-800-722-7549 or visit us at http://www.wextech.ca

 Per: Donna Shum, Corporate Secretary